Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M568Revenue (TTM) $M18.9Net Margin (%)-383.8Altman Z-Score1.0
Enterprise Value $M485EPS (TTM) $-0.7Operating Margin %-391.1Piotroski F-Score2
P/E(ttm)--Beneish M-Score-4.6Pre-tax Margin (%)-383.8Higher ROA y-yN
Price/Book7.010-y EBITDA Growth Rate %--Quick Ratio5.3Cash flow > EarningsN
Price/Sales38.75-y EBITDA Growth Rate %-14.4Current Ratio5.3Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-80.2Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)-104.3Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M145ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with RIGL

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

RIGL is held by these investors:



RIGL: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Duliege Anne-MarieChief Medical Officer 2017-07-05Sell5,000$2.6943.87view
Duliege Anne-MarieChief Medical Officer 2017-01-03Sell5,000$2.4160.58view
PAYAN DONALD GEVP, Pres. Discovery&Research 2016-08-30Sell5,303$4-3.25view
PAYAN DONALD GEVP, Pres. Discovery&Research 2015-06-10Sell41,666$3.685.16view
PAYAN DONALD GEVP, Pres. Discovery&Research 2015-04-01Sell10,000$3.753.2view
VANCE DOLLYEVP Corp. Affairs, G.C., Sect. 2014-12-18Sell1,000$2.2274.32view
VANCE DOLLYEVP Corp. Affairs, G.C., Sect. 2014-12-18Sell1,000$2.2274.32view
PAYAN DONALD GEVP, Pres. Discovery&Research 2014-09-03Sell20,000$2.5651.17view
PAYAN DONALD GEVP, Pres. Discovery&Research 2014-02-24Sell20,000$3.714.31view
BVF PARTNERS L P/IL10% Owner 2013-11-19Sell484,622$2.6446.59view

Quarterly/Annual Reports about RIGL:

News about RIGL:

Articles On GuruFocus.com
Rigel Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Option To Purchase A Oct 10 2017 
Rigel Announces Pricing Of Public Offering Of Common Stock Oct 04 2017 
Rigel Announces Proposed Public Offering Of Common Stock Oct 03 2017 
Fostamatinib Meets Pre-Specified Primary Endpoint in Stage 1 of Autoimmune Hemolytic Anemia (AIHA) P Oct 03 2017 
Rigel Provides Update on FDA Review of Fostamatinib for ITP Oct 02 2017 
Rigel to Present at Cantor Fitzgerald Global Healthcare Conference Sep 19 2017 
Rigel Welcomes Brian Kotzin, M.D. to Board of Directors Aug 25 2017 
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) Aug 18 2017 
Rigel Announces Second Quarter 2017 Financial Results and Provides Company Update Aug 01 2017 
Rigel Announces Conference Call and Webcast to Report Second Quarter 2017 Financial Results Jul 25 2017 
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}
FEEDBACK